Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients.
about
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitroIodine alters gene expression in the MCF7 breast cancer cell line: evidence for an anti-estrogen effect of iodineHistone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells.Cyclin D1 and Rb protein expression and their correlation with prognosis in patients with colon cancer.CIViC databaseRSF1 and not cyclin D1 gene amplification may predict lack of benefit from adjuvant tamoxifen in high-risk pre-menopausal women in the MA.12 randomized clinical trial.Cyclin D as a therapeutic target in cancerPathways to tamoxifen resistance.Analysis of cyclins A, B1, D1 and E in breast cancer in relation to tumour grade and other prognostic factorsCell cycle and anti-estrogen effects synergize to regulate cell proliferation and ER target gene expression.Regulation of hormonal therapy resistance by cell cycle machinery.Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen.Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention.High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers.Palbociclib: an evidence-based review of its potential in the treatment of breast cancerTailoring to RB: tumour suppressor status and therapeutic response.Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells--identification of a novel androgen response element.Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells.Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer.SLUG-induced elevation of D1 cyclin in breast cancer cells through the inhibition of its ubiquitination.The role of oncogenes in gastrointestinal cancer.Progesterone receptor-cyclin D1 complexes induce cell cycle-dependent transcriptional programs in breast cancer cells.Cyclin D1 expression in colorectal cancer is a favorable prognostic factor in men but not in women in a prospective, population-based cohort studyAnti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells.Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC studyOvercoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 InhibitorsCyclinD1 protein plays different roles in modulating chemoresponses in MCF7 and MDA-MB231 cellsReliability of cyclin A assessment on tissue microarrays in breast cancer compared to conventional histological slidesGene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer.Activity and intracellular location of estrogen receptors alpha and beta in human bronchial epithelial cells.Zinc protoporphyrin regulates cyclin D1 expression independent of heme oxygenase inhibition.Association of Over-Expressed Estrogen Receptor Alpha with Development of Tamoxifen Resistant Hyperplasia and Adenocarcinomas in Genetically Engineered MiceProgress with palbociclib in breast cancer: latest evidence and clinical considerations.Longer survival in patients with breast cancer with cyclin d1 over-expression after tumor recurrence: longer, but occupied with diseaseEMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry.Predictive biomarkers in breast cancer: their value in neoadjuvant chemotherapy.The 11q13-q14 amplicon: clinicopathological correlations and potential drivers.Challenges in the management of advanced, ER-positive, HER2-negative breast cancer.Metastatic breast cancer: The Odyssey of personalization.
P2860
Q21195212-1A9F5D2E-776C-4461-B782-04BB4A9E512BQ24645043-56FCF44B-8186-49E4-B3F6-C3239C7A5C11Q25257349-E019B8B8-392A-4A2A-BE64-8A52A5670805Q25257909-2530155F-051C-4BB6-A744-C6B633879234Q27612411-21EB0C16-484B-4475-9A78-E1B1CFB99369Q27852757-D84C8F5F-B034-44DA-8A03-90C14A56F280Q28242623-F68243DC-2FE8-42ED-ACB2-E7097839F6E8Q30441001-4448D9D6-F1EB-4622-9132-68A84048078FQ33483633-1F39DA0E-01BA-4050-B9F9-13E0FD18CAA9Q33603027-203E3248-C18F-4DC7-992C-4A75DB8B7EBEQ33635621-84122123-DCFD-4434-A0F7-2730F0AB2FC1Q33751778-D7A41AA5-1061-41A4-B7DA-249EDE77EDEEQ33820278-1F769AEA-57F8-4D26-8649-C5D3AF69B93DQ33867326-FDED35EA-205C-4224-A3ED-915591E857F8Q34027724-3B7202F5-EF6D-4651-82FA-55A208D4394CQ34040108-47C80AC3-9B2B-49CA-8589-FCF837A2A8BAQ34122589-284C8C75-B26F-467F-A729-0330BAE77A4AQ34369138-114C48F9-10CD-4D54-8D23-7A641347CF92Q34394399-A4FF2E1B-C620-4B5B-9650-81B077B8D89DQ34452617-E5F9E4FD-0A57-4DEC-B3C8-964817018B9AQ34616409-C71D0C58-2C29-4D8A-B3C5-E29C5B6EDB65Q35113788-A721BDDA-49CD-4816-879D-375FF586E7D0Q35231140-D9947861-76EF-4B41-9B95-B94DF0F48DF4Q35760937-B7A7F004-777D-4429-AECF-687B0F38F8D4Q36175746-9F485A06-090C-4CED-BEDB-C867F33DE0EBQ36245589-740D968C-A32B-4616-B124-5A3E12A168FBQ36420373-65104154-9BF4-4E0C-89C6-36D9CDE94D85Q36451013-44508A48-DA6A-4E42-9829-F23D34980EEAQ36614316-592B4925-A959-4280-9342-761842C6FD45Q37038663-0C8768EE-D900-4017-B9E2-4594DB001D47Q37399532-6FF0E52D-7896-4812-9F5A-EEBDCFFF3F79Q37479305-B0C2B1F3-2FCE-4C24-9FBC-540E94445C24Q37599164-B93274E5-1557-47E1-AE97-C2CA6703E26CQ37632170-D2AD7CCE-BA34-49F4-B5CB-AB99A4BE8EE2Q37705398-D7D6F607-C444-4BD2-AF75-73A61D5C99D3Q37843728-E58B2432-3C6F-4ACA-B24B-15B5887A0AD7Q38047337-4975DA6A-271F-4140-8E35-92FA93335FBBQ38066149-101B23CF-0C34-4C90-9D34-A04F94BF2233Q38502890-8CA1F6B2-D3B0-44C7-9BF9-1A06C236276EQ38901163-83B814D0-FDEC-4CF2-A54D-A13B3E108683
P2860
Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Cyclin D1 overexpression is a ...... pausal breast cancer patients.
@ast
Cyclin D1 overexpression is a ...... pausal breast cancer patients.
@en
Cyclin D1 overexpression is a ...... pausal breast cancer patients.
@nl
type
label
Cyclin D1 overexpression is a ...... pausal breast cancer patients.
@ast
Cyclin D1 overexpression is a ...... pausal breast cancer patients.
@en
Cyclin D1 overexpression is a ...... pausal breast cancer patients.
@nl
altLabel
Cyclin D1 overexpression is a ...... opausal breast cancer patients
@en
prefLabel
Cyclin D1 overexpression is a ...... pausal breast cancer patients.
@ast
Cyclin D1 overexpression is a ...... pausal breast cancer patients.
@en
Cyclin D1 overexpression is a ...... pausal breast cancer patients.
@nl
P2093
P2860
P921
P356
P1476
Cyclin D1 overexpression is a ...... pausal breast cancer patients.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6601831
P407
P577
2004-05-17T00:00:00Z
P5875
P6179
1045183988